Table 5.
Baseline SF-36 or SF-12 scores of patients in clinical trials of FM
| Mean score on health status domains (SD)† | Summary scores | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Health status measure used Reference (country) | n (% women) | Mean age (SD)† | PF | RP | BP | GH | VT | SF | RE | MH | PSC | MCS |
| SF-36 | ||||||||||||
| Arnold et al. (2004) (38) (USA) | 207 (89) | 49.1 | 45.5 | 17.0 | 31.9 | 50.4 | 23.8 | 58.3 | 59.1 | 63.7 | 29.8 | 45.2 |
| Assis et al. (2006) (52) (Brazil) | 60 (100) | 42.8 | 64.9 | 57.2 | ||||||||
| Bennett et al. (2003) (37)/Bennett et al.(2005) (9) (USA) | 315 (94) | 50 | 38.5 | 11.5 | 28 | 46.5 | 20 | 49.5 | 42 | 59.5 | 28.5 | 41.5 |
| Crofford et al. (2005) (39) (USA) | 529 (90) | 47.6 | 40.8 | 15.4 | 27.8 | 47.7 | 20.5 | 49.2 | 46.4 | 58.9 | ||
| Donaldson et al. (2001) (USA) (53) | 26 (93) | NR | 36.3 (24.3) | 6.3 (11.1) | 32.6 (20.2) | 44.1 (21.6) | 18.0 (14.4) | 40.0 (26.5) | 25.0 (26.5) | 57.2 (23.1) | ||
| Faull (2005) (13) (New Zealand) | 13 (100) | 46.3 (12.3) | 51.7 | 44.6 | 39.3 | 48.5 | 34.6 | 64.4 | 64.4 | 66.6 | ||
| Fregni et al. (2006) (54) (Brazil) | 32 (100) | 53.0 | 30.9 | 33.6 | 37.9 | 43.6 | 41.7 | 42.3 | 33.6 | 39.2 | ||
| Mannerkorpi et al. (2000) (55) (Sweden) | 26 (100) | 45.0 (8.0) | 44.3 (20.0) | 16.1 (29.0) | 24.7 (17.4) | 38.3 (16.8) | 22.5 (14.5) | 46.9 (26.9) | 47.6 (43.9) | 59.9 (20.4) | ||
| Neumann et al. (2001) (56) (Israel) | 48 (100) | 54.45 | 34 | 19 | 19 | 27 | 39 | 42 | 48 | 51 | ||
| Valim et al. (2003) (57) (Brazil) | 76 (100) | 46.8 | 55.0 | 23.1 | 34.9 | 49.8 | 31.4 | 52.2 | 39.8 | 43.0 | 36.3 | 35.7 |
| Vitorino et al. (2006) (58) (Brazil) | 50 (100) | 47.7 (8.8) | 35.5 | 16.7 | 19.7 | 34.6 | 29.6 | 38.5 | 15.0 | 40.4 | ||
| Zijlstra et al. (2005) (59) (the Netherlands) | 28.2 | 46.1 | ||||||||||
| SF-36 comparison treatment group studies‡(15) | ||||||||||||
| FM (USA) | 18 (94) | 51.2 (11.2) | 61.7 (24.0) | 38.9 (37.6) | 39.2 (20.8) | 60.1 (22.4) | 32.8 (22.4) | 61.1 (24.2) | 53.7 (44.5) | 68.2 (15.9) | ||
| Incontinence (USA) | 30 (90) | 76.9 (8.1) | 11.1 (18.7) | 21.7 (35.2) | 46.6 (31.3) | 42.6 (20.7) | 40.7 (21.5) | 62.5 (32.3) | 42.2 (45.4) | 69.6 (21.1) | ||
| Prostate cancer (USA) | 12 (0) | 63.4 (9.7) | 93.3 (20.0) | 91.7 (28.9) | 80.8 (23.7) | 69.8 (21.8) | 73.8 (25.6) | 85.4 (26.6) | 97.2 (9.6) | 79.3 (16.2) | ||
| COPD (USA) | 13 (62) | 66.7 (3.7) | 23.1 (15.2) | 9.6 (21.7) | 58.5 (24.2) | 35.5 (15.3) | 40.8 (14.1) | 52.9 (18.5) | 41.0 (45.5) | 59.1 (15.3) | ||
| AIDS (USA) | 35 (14) | 39.5 (6.0) | 47.4 (33.3) | 87.9 (31.1) | 40.5 (33.2) | 30.1 (22.9) | 35.3 (23.6) | 52.5 (34.1) | 41.9 (44.5) | 69.6 (22.8) | ||
| Hyperlipidaemia (USA) | 213 (47) | 46.1 (9.0) | 89.6 (15.2) | 80.8 (33.1) | 73.1 (22.3) | 76.5 (16.0) | 61.4 (19.8) | 87.7 (18.5) | 80.3 (30.2) | 75.6 (16.6) | ||
| SF-12 | ||||||||||||
| Hidalgo et al. (2006) (60) (Spain) | 35 (93) | 47.2 (7.9) | 27.7 (7.7) | 29.5 (37.5) | ||||||||
SF-36, short-form health survey (36 items): SF-12, short-form health survey (12 items); PF, physical functioning; RP, role functioning difficulties caused by physical problems; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role functioning difficulties caused by emotional problems; MH, mental health; PCS, physical component summary; MCS, mental component summary. Higher scores indicate better health status. Pain conditions: FM, fibromyalgia; COPD, chronic obstructive pulmonary disease; AIDS, acquired immune deficiency syndrome.
SD is not shown when mean values were calculated by averaging baseline scores across treatment groups.
Schlenk et al. (1998) (15) reported on baseline data of subjects from six treatment studies of six chronic disorders.